Evidence supporting the use of: Arsenic
For the health condition: Leukemia

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 5

Arsenic, specifically in the form of arsenic trioxide (ATO), has robust scientific validation for its use in the treatment of a specific type of leukemia known as acute promyelocytic leukemia (APL). Arsenic trioxide was introduced into modern medicine after traditional use in Chinese medicine, but its current acceptance and use are based on extensive clinical research and regulatory approval. Multiple clinical trials have demonstrated that ATO is highly effective, particularly in patients with relapsed or refractory APL. It induces remission by promoting the degradation of the PML-RARα fusion protein, leading to differentiation and apoptosis of leukemic cells. Arsenic trioxide is now a standard component of frontline therapy for APL, often used in combination with all-trans retinoic acid (ATRA). The drug has been approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) for this indication. The evidence supporting arsenic's efficacy in APL is strong, with survival rates significantly improved compared to previous treatment regimens. Its use is not generalized to all types of leukemia but is specifically tailored to APL due to the unique molecular pathology of the disease. Side effects are well-characterized and manageable in most cases. Overall, arsenic trioxide is one of the most significant advances in leukemia therapy in recent decades, with its use for APL being firmly grounded in scientific evidence.

More about Arsenic
More about Leukemia

Products containing Arsenic

We currently have no products on Vitabase that contain this ingredient.